Cytogel Pharma key facts
as of Oct 2026- Operator of a bio-pharmaceutical company intended to assist with the discovery and development of safe and innovative treatments to finally resolve moderate to severe pain.
- Cytogel Pharma is valued at approximately $47.0M as of Oct 2026, set at its later-stage round, Oct 2024; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $32.8M across 4 recorded rounds; the latest was Seed Round ($1.8M) in Jun 2023.
- Notable investors include New Ground Ventures, Westway Capital, Centripetal Capital Partners, Cytogel Venture, John Fernandes.
- Cytogel Pharma has filed 14 Form Ds with the SEC since 2010, most recently Oct 2024 ($1.8M sold to 18 investors).
- Status: Privately Held (backing).
Valued at $47.0M at its later-stage round, Oct 2024. Nothing has traded since.
- ·Watch Cytogel Pharma: the Monday email on marks, rounds and moves
Cytogel Pharma funding rounds
4 roundsWho backs Cytogel Pharma
5Cytogel Pharma valuation
Cytogel Pharma was valued at $47 million at its later-stage round in Oct 2024. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has Cytogel Pharma raised?
Cytogel Pharma has raised $32.8 million in total; 4 of its rounds are on record, from 2013 on. The largest on record was a $956,905 seed round in Sep 2019; the most recent was a $1.8 million seed round in Jun 2023.
Cytogel Pharma has filed 14 Form Ds with the SEC since 2010, most recently in Oct 2024 ($1.8 million sold to 18 investors).
Cytogel Pharma investors
5 investors are on record for Cytogel Pharma, including New Ground Ventures, Westway Capital, Centripetal Capital Partners and Cytogel Venture. The seed round in Jun 2023 drew 18 investors.
About Cytogel Pharma
Operator of a bio-pharmaceutical company intended to assist with the discovery and development of safe and innovative treatments to finally resolve moderate to severe pain. The company offers significant potential both as platform technologies, value product candidates, and drug delivery hydrogels that represent a breakthrough in the treatment of pain, enabling patients to get treatment properly, resulting in a likelihood of successful treatment.
- Sector
- Healthcare
- HQ
- Darien, CT, United States
- Founded
- 2006
- Employees
- 9
- Website
- cytogelpharma.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.